Nov 6, 2025 07:01AM Axsome acquires Avenue's subsidiary for epilepsy drug development

Oct 2, 2025 06:47AM H.C. Wainwright Reiterates Buy Rating on Fortress Biotech (FBIO)

Aug 21, 2025 06:07AM Fortress Biotech (FBIO) PT Lowered to $17 at H.C. Wainwright

Aug 14, 2025 05:21PM Fortress Biotech (FBIO) Tops Q2 EPS by 45c

Jul 14, 2025 08:31AM Journey Medical expands Emrosi payer coverage to 65% of commercial lives

Jul 7, 2025 08:32AM FDA grants orphan drug status to Mustang Bio's brain cancer treatment

Jun 24, 2025 08:31AM Journey Medical Corp (DERM) set to join Russell 2000 and 3000

Jun 20, 2025 08:32AM Journey Medical Corp (DERM) Announces Emrosi Data Analysis to be Presented at SDPA

May 30, 2025 10:48AM Fortress Biotech (FBIO) Closes Sale of Checkpoint Therapeutics

May 15, 2025 06:40PM Fortress Biotech (FBIO) Misses Q1 EPS by 48c

Mar 17, 2025 08:56AM Partex and Fortress Biotech (FBIO) Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform

Mar 9, 2025 10:07PM Sun Pharma to Acquire Checkpoint Therapeutics

Mar 5, 2025 04:17PM Mustang Bio (MBIO) Regains Nasdaq Compliance

Mar 5, 2025 04:01PM Journey Medical Corp (DERM) Announces Publication of the Phase 3 Clinical Trial Results of Emrosi

Feb 27, 2025 04:06PM Mustang Bio (MBIO) Announces Sale of Fixed Assets and Exit of Facility

Jan 27, 2025 08:31AM Fortress Biotech (FBIO) Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination

Jan 6, 2025 08:01AM Fortress Biotech (FBIO) and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101

Nov 18, 2024 06:56AM Fortress Biotech (FBIO) PT Raised to $26 at H.C. Wainwright

Nov 14, 2024 09:18PM Fortress Biotech (FBIO) Misses Q3 EPS by 76c

Nov 12, 2024 08:31AM Mustang Bio (MBIO) Receives Positive Listing Determination from Nasdaq

Nov 7, 2024 08:32AM Mustang Bio (MBIO) Granted FDA Orphan Drug Designation for MB-108

Nov 4, 2024 07:01AM Journey Medical Corp (DERM) Announces U.S. FDA Approval of Emrosi

Oct 24, 2024 02:10PM Mustang Bio (MBIO) Announces Exercise of Warrants for $4 Million Gross Proceeds

Sep 27, 2024 05:00PM Fortress Biotech (FBIO) Files for 6.19M Share Offering by Selling Stockholders

Sep 20, 2024 08:31AM Fortress Biotech (FBIO) Prices 3.94M Sharee Offering at $1.65/sh

Sep 16, 2024 07:32AM Checkpoint Therapeutics (CKPT) Presents Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma

Aug 14, 2024 05:06AM Fortress Biotech (FBIO) PT Raised to $13 at Roth/MKM

Aug 13, 2024 04:25PM Fortress Biotech (FBIO) Reports Q2 Loss of $0.73/sh

Jul 25, 2024 08:31AM Fortress Biotech (FBIO) Reduces Total Debt, Enters $35M Term Loan with Oaktree with Maturity in 2027

Jul 25, 2024 07:31AM Checkpoint Therapeutics (CKPT) Announces FDA Acceptance of BLA Resubmission of Cosibelimab

Jun 20, 2024 04:08PM Fortress Biotech (FBIO) Files for 2.35M Share Offering by Selling Stockholders

Jun 20, 2024 08:01AM Mustang Bio (MBIO) Announces 6.13M Share Offering at $0.41/sh

Jun 17, 2024 08:31AM Mustang Bio (MBIO) Reports Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Trial of MB-106